Stock Analysis on Net
Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Price to Operating Profit (P/OP)
since 2005

Microsoft Excel

Paying user area

Try for free

Abiomed Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Abiomed Inc., P/OP, long-term trends, calculation

Microsoft Excel
P/OP = Share price1, 2, 3 ÷ Operating profit per share1 Operating profit per share1 = Income (loss) from operations1
(in thousands)		 ÷ No. shares of common stock outstanding2
May 20, 2022 = ÷ = ÷
May 21, 2021 = ÷ = ÷
May 21, 2020 = ÷ = ÷
May 23, 2019 = ÷ = ÷
May 24, 2018 = ÷ = ÷
May 25, 2017 = ÷ = ÷
May 26, 2016 = ÷ = ÷
May 28, 2015 = ÷ = ÷
May 28, 2014 = ÷ = ÷
May 28, 2013 = ÷ = ÷
Jun 4, 2012 = ÷ = ÷
Jun 2, 2011 = ÷ = ÷
Jun 8, 2010 = ÷ = ÷
Jun 8, 2009 = ÷ = ÷
Jun 16, 2008 = ÷ = ÷
Jun 13, 2007 = ÷ = ÷
Jun 14, 2006 = ÷ = ÷
Jun 14, 2005 = ÷ = ÷

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31), 10-K (reporting date: 2016-03-31), 10-K (reporting date: 2015-03-31), 10-K (reporting date: 2014-03-31), 10-K (reporting date: 2013-03-31), 10-K (reporting date: 2012-03-31), 10-K (reporting date: 2011-03-31), 10-K (reporting date: 2010-03-31), 10-K (reporting date: 2009-03-31), 10-K (reporting date: 2008-03-31), 10-K (reporting date: 2007-03-31), 10-K (reporting date: 2006-03-31), 10-K (reporting date: 2005-03-31).

1 US$

2 Data adjusted for splits and stock dividends.

3 Closing price as at the filing date of Abiomed Inc. Annual Report.

Share Price Trend
The share price experienced significant fluctuations over the analyzed period. Initially, there was moderate growth from $9.25 in 2005 to approximately $22.17 in 2013. From 2013 onward, the share price sharply increased, peaking notably in 2018 at $394.46. However, following this peak, a downward correction occurred through 2019 and 2020, with a price decline to $196.32. The share price partially recovered in 2021 to $280 but declined again slightly in 2022 to $235.75. Overall, the share price shows intense volatility with a strong upward trend in the medium term followed by corrections.
Operating Profit per Share Trend
Operating profit per share (OPPS) data reveals a gradual improvement over time. From 2005 to 2007, the company incurred losses per share ranging from -$0.12 to -$0.88, with fluctuations around negative territory until 2008. Starting from 2012, the company shifted to positive operating profits, with progressive increases from $0.04 in 2012 to a peak of $5.54 in 2020. After the peak in 2020, OPPS decreased moderately to $5.07 in 2021 and further to $3.09 in 2022, indicating some recent operational challenges or increased expenses.
P/OP Ratio Analysis
The Price to Operating Profit (P/OP) ratio data is available from 2013 onward and reflects market valuation relative to operating earnings. Initial ratios were extremely elevated at 512.24 in 2013, indicating potentially overvalued share prices or very low earnings at that time. From 2014 to 2018, the ratio declined to more moderate levels between approximately 35 and 111, showing market adjustments and improved earnings. Nonetheless, the ratio remained volatile, with spikes in 2016 (111.65) and 2019 (111.65), corresponding with variations in earnings and share price. The ratio decreases in 2021 to 55.25 but rises again to 76.33 in 2022, suggesting fluctuating market sentiment or changes in profitability.
Overall Insights
The analyzed financial data shows a company transitioning from operating losses to solid profitability between 2005 and 2020. This transition is accompanied by a substantial rise in share price, particularly between 2013 and 2018. Despite this upward trend, the company’s share price has experienced notable volatility and post-peak corrections. The P/OP ratio indicates periods when the market may have overvalued the shares relative to operating profits, followed by subsequent readjustment. Recent declines in both operating profit per share and share price suggest emerging operational or market challenges that may warrant closer attention.

Comparison to Competitors

Abiomed Inc., P/OP, long-term trends, comparison to competitors

Microsoft Excel
Abiomed Inc. Abbott Laboratories Intuitive Surgical Inc. Medtronic PLC UnitedHealth Group Inc.
May 20, 2022
May 21, 2021
May 21, 2020
May 23, 2019
May 24, 2018
May 25, 2017
May 26, 2016
May 28, 2015
May 28, 2014
May 28, 2013
Jun 4, 2012
Jun 2, 2011
Jun 8, 2010
Jun 8, 2009
Jun 16, 2008
Jun 13, 2007
Jun 14, 2006
Jun 14, 2005

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31), 10-K (reporting date: 2016-03-31), 10-K (reporting date: 2015-03-31), 10-K (reporting date: 2014-03-31), 10-K (reporting date: 2013-03-31), 10-K (reporting date: 2012-03-31), 10-K (reporting date: 2011-03-31), 10-K (reporting date: 2010-03-31), 10-K (reporting date: 2009-03-31), 10-K (reporting date: 2008-03-31), 10-K (reporting date: 2007-03-31), 10-K (reporting date: 2006-03-31), 10-K (reporting date: 2005-03-31).